Of the many other small-to-medium scale medtech deals in 2016, the more eye-catching were:
Smaller But Eye-Catching Medtech Deals
Not all of the key medtech deals of 2016 were blockbusters. Herein are some of the more interesting smaller deals of the year.
More from Archive
More from In Vivo
• By
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
• By
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.